This company has been acquired
Stealth BioTherapeutics Management
Management criteria checks 1/4
Key information
Reenie McCarthy
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31
CEO
Reenie McCarthy (57 yo)
Ms. Irene P. McCarthy, also known as Reenie, J.D., has been President, Chief Executive Officer and Secretory of Stealth BioTherapeutics Corp (formerly known as Stealth BioTherapeutics Inc.) since October 2...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.4yrs | no data | 0.19% $ 45.9k | |
| Independent Non-Employee Director | 4.4yrs | no data | 0% $ 0 | |
| Independent Non-Employee Director | 4.4yrs | no data | 0% $ 0 | |
| Independent Director | 3.3yrs | no data | 0% $ 0 | |
| Chairman of the Board | 4.4yrs | no data | 0% $ 0 | |
| Director | 1.9yrs | no data | 0% $ 0 | |
| Non-Employee Director | 5.3yrs | no data | 0.11% $ 25.9k |
Experienced Board: MITO's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/16 15:33 |
| End of Day Share Price | 2022/11/15 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stealth BioTherapeutics Corp is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |